ClinicalTrials.gg
RecruitingNCT07612254REPEATUpdated Nov 16, 2026

aPBI Re-irradiation

A Phase 1/2 interventional study of Reirradiation in Breast Cancer Recurrent, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Dartmouth-Hitchcock Medical Center · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center — 6 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Dartmouth-Hitchcock Medical Center.

Planned enrollment
17th of 34
30 · median 30
Started
2026
with 1 other
Phase 1/2
Only one
of the 44
Registered
43rd of 44
by date

Among the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, this one is the 17th largest by planned enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2026, is the only one in phase 1/2, and was the 43rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, or all of them as a file.
02

Study summary

This study is to determine whether acute treatment-associated adverse events following breast re-irradiation with aPBI are acceptably low and to assess local control following breast re-irradiation with aPBI. An exploratory aim is to assess cosmetic outcomes following breast re-irradiation with aPBI.

03

Conditions studied

  • Breast Cancer Recurrent

Browse trials for

Keywords

  • Ipsilateral
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who have -confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy.
  2. Patients must have received prior radiotherapy to the breast
  3. Patients must have an intact, involved breast.
  4. Patients must meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation.

    • Grade 1-2 disease
    • ER-positive histology
    • Tumor size up to 2 cm
    • Patient's age 40 or older
  5. Patients who will undergo breast radiation therapy at D-H Lebanon, D-H St. Johnsbury, or Cheshire Medical Center.
  6. Patients must have a lumpectomy cavity that can be delineated on CT scan.
  7. Patients who are able to provide .
  8. Females of must have a negative urine or serum pregnancy test within 14 days of study entry.
  9. Females of childbearing potential must not be pregnant and not lactating and willing to use medically acceptable form of during radiation therapy.

Exclusion criteria

Exclusion Criteria

Patients who meet any of the criteria below may NOT participate in this study:

  1. Patients who have not received prior radiotherapy to the ipsilateral breast.
  2. Patients who do not meet ASTRO 2023 guidelines for a strong recommendation for partial breast irradiation, including those who meet criteria for conditionally recommended, conditionally not recommended, and not recommended for partial breast irradiation.
  3. Patients who are \< 40 years of age.
  4. Patients with breast implants or other breast reconstruction.
  5. Patients who received a prior course of aPBI or breast brachytherapy in the ipsilateral breast.
  6. Patients who are actively receiving treatment or within 1 year of treatment from another , excluding non-melanoma skin cancers.
  7. Patients who are pregnant.
  8. Patients who are unable to provide .
  9. Patients who decline participation in the study.
  10. Patients with active systemic lupus erythematosus, or any history of scleroderma, dermatomyositis with active rash are excluded.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    aPBI Re-irradiation

    Patients who have histologically-confirmed, second, ipsilateral breast cancer which was diagnosed more than one year after completing breast conserving therapy and have received or are receiving re-irradiation for in-breast recurrence of breast cancer.

    Radiation: Reirradiation

Interventions

  • RadiationReirradiation

    aPBI, which is routinely used to treat patients who have previously not been irradiated, with a dose of 30 Gy in 5 fractions using a VMAT technique.

06

What researchers measure

Primary outcomes

  1. Treatment-associated toxicity

    Acceptably low acute treatment-associated adverse events following breast re-irradiation with aPBI.

    Time frame: Within 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2032, 70 months after the start.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 70 months is close to that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 28, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Apr 28, 2032
CompletionEst.
Apr 2033
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
Dartmouth-Hitchcock Medical Center is now Recruiting
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesContact added A•••@hitchcock.org · •••6600Contact added l•••@hitchcock.org · •••6600Contact added (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Dartmouth-Hitchcock Medical Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesContact added A•••@hitchcock.org · •••6600Contact added l•••@hitchcock.org · •••6600Contact added (no phone or email listed)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612254
Responsible party
Lesley A. Jarvis (Physician Radiation Oncology, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
May 28, 2026
Start date
Jun 3, 2026
Primary completion
Apr 28, 2032 (estimated)
Completion
Apr 2033 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion